Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma

Introduction Benralizumab, an interleukin-5 receptor alpha–directed cytolytic anti-eosinophil monoclonal antibody, was recently approved as add-on maintenance treatment for patients aged 12 years and older with uncontrolled asthma with eosinophilic inflammation.